The use of combination therapy increases at second line and in more severe patients. In the US, combination therapy is apparent even at first-line treatment of moderate and severe Alzheimer’s disease, indicating that neurologists are willing to initiate therapy of an advanced patient with a cholinesterase inhibitor and memantine.
Your key questions answered
· How does each drug’s patient share vary by disease severity and line of therapy?
· What can be done to influence the patient pathway to increase market share?
· What is the realistic patient population that a new market entrant can target?
· How has generic donepezil affected prescribing behaviors in the US?
Request a Sample for or Inquire before buying the report@
Alzheimer's Disease
Features and benefits
· Quantify the prevalent, diagnosed, and treated Alzheimer’s disease patient populations in each of the seven major markets.
· Analyze physician prescribing habits by disease severity and line of therapy.
· Understand how treatment and compliance rates vary according to disease severity.
· Identify opportunities for increasing market share through effective product positioning.
Major points covered in Table of Contents of this report include:
Executive summary
COUNTRY TREATMENT TREES
DISEASE DEFINITION AND DIAGNOSIS
PATIENT SEGMENTATION
CURRENT TREATMENT OPTIONS
BIBLIOGRAPHY
See More Healthcare Market Research Reports
Report Details :
Published: March 2012
Published: March 2012
No. of Pages:
Price: Single User License - US $ 7600
Corporate user License- US $ 19000
